Class / Patent application number | Description | Number of patent applications / Date published |
514038000 | Two saccharide radicals bonded through only oxygen to adjacent ring carbons of the cyclohexyl ring | 39 |
20080300199 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 12-04-2008 |
20120214759 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS - A method for treating a | 08-23-2012 |
20130237489 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS - A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: | 09-12-2013 |
20140256665 | Aminoglycoside and Azole Compositions and Methods - The present invention relates to novel fungicidal compound including an aminoglycoside analog having certain substituents at the 6 position of ring III that exhibit improved antifungal activity but possess minimal antibacterial properties in combination with fungicidal azoles. The aminoglycoside compounds are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease. | 09-11-2014 |
20140357590 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS - A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: | 12-04-2014 |
20150352136 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS - A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders. | 12-10-2015 |
20160074425 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS - A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: | 03-17-2016 |
514039000 | Three or more saccharide radicals (e.g., neomycin, etc.) | 32 |
20080293649 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 11-27-2008 |
20100144662 | AMINOGLYCOSIDE ANTIBIOTICS TARGETING BACTERIAL 16S RIBOSOMAL RNA - The present invention relates to paromamine-based compounds according to formula I having selective antimicrobial activity directed at ribosomal 16S RNA. Furthermore, the invention is directed to the use of said compounds for preparing a medicament, pharmaceutical preparations and methods for preparing said compounds | 06-10-2010 |
20100210578 | Prevention/Treatment of Ichthyosis Vulgaris, Atopy and Other Disorders - The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant allele of the filaggrin gene. | 08-19-2010 |
20100267654 | RIFAMYCIN DERIVATIVES - Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: | 10-21-2010 |
20100298252 | METHODS AND COMPOSITIONS FOR OPHTHALMIC TREATMENT OF FUNGAL AND BACTERIAL INFECTIONS - The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent, and an antimicrobial agent. | 11-25-2010 |
20110118202 | Molecules which Bind to the Dimerization Initiation Site (DIS) of HIV RNA, Their Synthesis and Their Applications as Drugs - The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening a new anti-HIV approach. The crystal structures and bio-chemical experiments showed that the DIS of HIV-1 genomic RNA is a target for new anti-HIV drugs and that those drugs could be derived from aminoglycosides. The results revealed that binding of aminoglycosides to the DIS is specific regarding both the aminoglycoside family and the RNA subtype. | 05-19-2011 |
20110190233 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE - The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. | 08-04-2011 |
20110218168 | SUBSTITUTED POLYAMINES AS INHIBITORS OF BACTERIAL EFFLUX PUMPS - Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof. | 09-08-2011 |
20110275586 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 11-10-2011 |
20120101056 | Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same - The present invention is directed to a composition for treating bacterial skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of framycetin sulphate used in treating bacterial skin infections, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and an anti bacterial agent in the form of framycetin sulphate, are incorporated in cream base for use in treating bacterial skin infections with allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition. | 04-26-2012 |
20120122809 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 05-17-2012 |
20120157397 | TRIMETHYLAMINE-CONTAINING COMPOUNDS FOR DIAGNOSIS AND PREDICTION OF DISEASE - The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases. | 06-21-2012 |
20120258925 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 10-11-2012 |
20120264705 | ANTIMICROBIAL COMPOSITIONS COMPRISING 15-HETRE AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing. | 10-18-2012 |
20120283207 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 11-08-2012 |
20120283208 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 11-08-2012 |
20120283209 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 11-08-2012 |
20130005674 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 01-03-2013 |
20130178438 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 07-11-2013 |
20130184230 | COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND A BETA-LACTAM ANTIMICROBIAL AGENT, MUPIROCIN OR CHLORHEXIDINE - This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with another antimicrobial agent selected from the group consisting of a beta-lactam antimicrobial agent, mupirocin and chlorhexidine or a pharmaceutically acceptable derivative thereof, for the prevention and/or treatment of microbial infections. | 07-18-2013 |
20140088032 | TREATMENT OF MASTITIS - The invention relates to a veterinary composition for intramammary administration comprising a combination of an antibacterial agent and a Toll-Like-Receptor (TLR) agonist and to the use of said composition for the treatment of mastitis in lactating ruminants. | 03-27-2014 |
20140206636 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 07-24-2014 |
20140206637 | Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked. | 07-24-2014 |
20140243280 | Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable Thereby - The invention relates to drug development and synthetic chemistry, in particular to the manufacture of biologically active compounds based on naturally occurring molecules. It also relates to novel biologically active compounds, for example aminoglycoside antibiotics, in a substantially pure regioisomeric form. | 08-28-2014 |
20140357591 | CONJUGATED ANTIMICROBIAL AGENTS - Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry. | 12-04-2014 |
20150080329 | PHARMACEUTICAL COMPOSITIONS COMPRISING DHA, EPA, AND/OR GLA AND AN ANTIBIOTIC AGENT AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DHA, EPA and/or GLA, used in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection. | 03-19-2015 |
20150087611 | Multi-step Connective Tissue Stabilization Method and Stabilized Tissue Formed Thereby - A multi-step stabilization method for connective tissue is described. Stabilized tissues can exhibit increased resistance to degradation due to enzyme activity, fatigue and storage. The multi-step method includes a first step during which the tissue can be incubated with a glycosaminoglycanase inhibitor, a second step during which the tissue can be incubated with a crosslink activator and/or a phenolic compound, and a third step during which the tissue can be incubated with a second crosslink activator. | 03-26-2015 |
20150099713 | METHOD OF TREATING CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME - Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufactiurc of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent. | 04-09-2015 |
20160038438 | COMBINATION OF NORDIHYDROGUAIARETIC ACID AND AN AMINOGLYCOSIDE - The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections. | 02-11-2016 |
20160067179 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 03-10-2016 |
20160158262 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME - The present invention provides a method for treating irritable bowel syndrome (IBS) in a subject in need thereof. The treatment can include administering about 550 mg of rifaximin three times per day and about 500 mg of neomycin two times per day for 14 days to the subject to treat the IBS. In certain embodiments, the IBS is constipation predominant IBS (C-IBS). | 06-09-2016 |
20180022756 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING SENSORY HAIR CELL DEATH | 01-25-2018 |